Pulsenmore Ltd. Ordinary Shares

Pulsenmore has priced a private placement expected to raise approximately $7.5 million in gross proceeds from a single healthcare-focused institutional investor. The company will sell 1,562,500 ordinary shares, or pre-funded warrants in lieu thereof, along with ordinary warrants to purchase up to 1,562,500 ordinary shares, at a combined price of $4.80 per ordinary share and accompanying warrant. The ordinary warrants have an exercise price of $4.80 per share, are exercisable immediately, and expire five years from issuance. Pulsenmore intends to use the net proceeds for marketing and commercialization activities, working capital, and general corporate purposes, with closing anticipated on or about June 26, 2026.

Pulsenmore shares surged as much as 280% after the company entered a strategic partnership with Ouma Health, a U.S. provider of virtual maternity care solutions. The collaboration will integrate Pulsenmore's FDA-authorized home ultrasound platform into Ouma Health's virtual maternity care platform, enabling clinicians to extend prenatal ultrasound monitoring into patients' homes. Pulsenmore closed Wednesday at $6.59, up 93.26%. Other notable biotech gainers included IceCure Medical, which rose over 50% after a peer-reviewed article in the International Journal of Surgery validated its ProSense cryoablation technology for early-stage breast cancer, and Silence Therapeutics, which gained 26% ahead of topline Phase 2 results for its lead drug candidate Divesiran expected in August 2026.